A View of Chimerix Inc. (CMRX) Stock’s Fundamentals and Valuations

As of right now, Chimerix Inc. [CMRX] is trading at $1.99, climbing up 0.51%. An important factor to consider is whether the stock is rising or falling in short-term value. The CMRX shares have lost -8.29% over the last week, with a monthly amount drifted -16.03%, and not seem to be holding up well over a long-time horizon.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

On 6, September 2022, Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference. In a post published today on Yahoo Finance, Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded corporate presentation at the H.C. Wainwright 24th Annual Global Investment Conference made available on Monday, September 12, 2022 at 7:00 a.m. ET.

From an analyst’s perspective:

Chimerix Inc. [NASDAQ: CMRX] stock has seen the most recent analyst activity on September 07, 2022, when CapitalOne initiated its Overweight rating and assigned the stock a price target of $7. Previously, Maxim Group started tracking the stock with Buy rating on April 29, 2021, and set its price target to $20. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $21 on March 31, 2021. Jefferies initiated its recommendation with a Buy and recommended $21 as its price target on March 31, 2021. JP Morgan downgraded its rating to Underweight for this stock on February 14, 2018. In a note dated February 02, 2018, H.C. Wainwright initiated an Buy rating and iterated a target price of $10 on this stock.

Through the last year, Chimerix Inc.’s stock price ranged from $1.27 to $7.42. Currently, Wall Street analysts expect the stock to reach $7.50 within the next 12 months. Chimerix Inc. [NASDAQ: CMRX] shares were valued at $1.99 at the most recent close of the market. An investor can expect a potential return of 276.88% based on the average price forecast.

Analyzing the CMRX fundamentals

Gross Margin for this corporation currently stands at +76.35% with Operating Margin at -4573.52%, Pretax Margin comes in at -8753.71%, and Net Margin reading is -8753.71%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9167 points at the first support level, and at 1.8433 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0467, and for the 2nd resistance point, it is at 2.1033.

Chimerix Inc. [CMRX] reported earnings per share of -$0.28 for its fiscal quarter that ended on 3/30/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.33/share, meaning a difference of $0.05 and a surprise factor of 15.20%. By comparison, the stated earnings for the previous quarter ended on 12/30/2021 were -$0.45 per share as compared to estimates of -$0.17 per share, a difference of $-0.28 representing a surprise of -164.70%.

Ratios To Look Out For

It is important to note that Chimerix Inc. [NASDAQ:CMRX] has a current ratio of 2.20. On the other hand, the Quick Ratio is 3.11, and the Cash Ratio is 2.96. Considering the valuation of this stock, the price to sales ratio is 275.95, the price to book ratio is 8.19.

Transactions by insiders

The next item on our agenda is insider trading, which has seen 2 insider purchases totaling 200,000 shares and 0 insider sales totaling 0 shares over the past 3 months. Recent insider trading involved Meyer Robert J., Director, that happened on May 19 when 11400.0 shares were purchased. Director, MIDDLETON FRED A completed a deal on May 19 to buy 20000.0 shares. Meanwhile, Chief Business Officer and CFO Andriole Michael T. bought 15000.0 shares on May 17.